Descartes-25 / Cartesian Therapeutics - LARVOL DELTA

Descartes-25 in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - P1 | N=9 | Terminated | Sponsor: Cartesian Therapeutics | Active, not recruiting ➔ Terminated; Phase 1 enrollment completed. Further clinical development terminated.

Trial termination • Hematological Malignancies • Multiple Myeloma • Oncology

Descartes-25 in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - P1 | N=9 | Active, not recruiting | Sponsor: Cartesian Therapeutics | Recruiting ➔ Active, not recruiting | Phase classification: P1/2 ➔ P1 | N=20 ➔ 9

Enrollment change • Enrollment closed • Phase classification • Hematological Malignancies • Multiple Myeloma • Oncology

Descartes-25 in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - P1/2 | N=20 | Recruiting | Sponsor: Cartesian Therapeutics | Trial primary completion date: Dec 2023 ➔ Dec 2024

Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology

Descartes-25 in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - P1/2 | N=20 | Recruiting | Sponsor: Cartesian Therapeutics | Trial completion date: Jan 2023 ➔ Dec 2024 | Trial primary completion date: Dec 2022 ➔ Dec 2023

Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology

Cartesian Therapeutics Doses Patient with First Allogeneic RNA Cell Therapy for Multiple Myeloma (BioSpace) - "Cartesian Therapeutics...today announced that it has dosed the first patient in a Phase 1/2a multicenter clinical study evaluating Descartes-25 in patients with multiple myeloma....'Patients with relapsed and/or refractory multiple myeloma have few treatment options remaining,' said Kenneth Anderson, M.D...'A cell therapy that locally delivers a combination of a BCMA-bispecific antibody and IL-12, without using lymphodepleting chemotherapy, is an elegant and highly innovative approach. If approved, it will be a welcome addition to our toolkit for treating this currently incurable disease.'"

Media quote • Trial status

Cartesian Therapeutics Doses Patient with First Allogeneic RNA Cell Therapy for Multiple Myeloma (PRNewswire) - "Cartesian Therapeutics...announced that it has dosed the first patient in a Phase 1/2a multicenter clinical study evaluating Descartes-25 in patients with multiple myeloma....The Phase 1/2a study (NCT05113342) is an open-label, multicenter, dose escalation trial for Descartes 25 in patients with relapsed and/or refractory multiple myeloma. The study aims to enroll twenty patients who have previously failed two or more lines of treatment to determine the safety and preliminary efficacy of Descartes-25."

Trial status • Hematological Malignancies • Multiple Myeloma • Oncology